News|Slideshows|April 30, 2025

April Pharmaceutical Industry Movers & Shakers

A monthly roundup of business and people news in the pharmaceutical industry.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

BioNTech Launches Public Exchange Offer for CureVac in $1.25B All-Stock Deal

ByNicholas Saraceno, Editor

October 23rd 2025

Moderna Ceases Development of mRNA-1647 After Failing to Reach Primary Goal in Clinical Trial

ByNicholas Jacobus

October 23rd 2025

Alkermes plc Acquiring Avadel Pharmaceuticals in $2.1 Billion Definitive Agreement

ByNicholas Jacobus

October 23rd 2025

What Impact will DTC Programs Have on Prescription Drug Prices?

ByMike Hollan,Chris O'Dell

October 23rd 2025

Pharmaceutical Executive Daily: Novo Nordisk's Board Shake-Up

ByNicholas Jacobus

October 22nd 2025

April Pharmaceutical Industry Movers & Shakers

Newsletter

Related Content

BioNTech Launches Public Exchange Offer for CureVac in $1.25B All-Stock Deal

Moderna Ceases Development of mRNA-1647 After Failing to Reach Primary Goal in Clinical Trial

Alkermes plc Acquiring Avadel Pharmaceuticals in $2.1 Billion Definitive Agreement

What Impact will DTC Programs Have on Prescription Drug Prices?

Pharmaceutical Executive Daily: Novo Nordisk's Board Shake-Up

Trending on PharmExec

Bob Mauch: Strengthening the Chain

Novo Nordisk Stock Reacts to Recent Board Changes

The Long-Term Outlook for MFN Pricing: Far-Reaching Issues and Considerations

What Impact will DTC Programs Have on Prescription Drug Prices?

Site Satisfaction Is the New Competitive Advantage